Sareum Holdings awarded grant for breast cancer chemical series

Cancer drug discovery business Sareum Holdings has been offered a grant from funding programme Biomedial Catalyst, which will provide financial support for the company's Fatty Acid Synthase (FASN) research programme.

Cancer drug discovery business Sareum Holdings has been offered a grant from funding programme Biomedial Catalyst, which will provide financial support for the company's Fatty Acid Synthase (FASN) research programme.

The £150,000 grant funding will enable Sareum to explore further the potential of its novel chemical series, which shows promising efficacy in breast cancel cell models, over the next nine months.

Sareum will receive the grant on the condition it contributes up to £50,000 from its working capital during the funding period, as well as a compliance review by the Technology Strategy Board and an agreement between both parties.

Sareum's Chief Executive, Dr. Tim Mitchell, said: "We are delighted to have been offered this financial support from the Biomedical Catalyst, which gives us the opportunity to demonstrate the potential of our novel FASN inhibitors.

"Success from this funding period may open up the opportunity of additional awards to advance further the programme. We believe this award is a positive validation of Sareum's science as competition for these grants is very strong."

The share price climbed 2.% to 1.02p by 09:37.

NR

Recommended

Marks & Spencer shares look cheap – should you buy in?
Retail stocks

Marks & Spencer shares look cheap – should you buy in?

Marks & Spencer shares have been a disappointment for investors for two decades. But with the company now on something of a comeback, Rupert Hargreave…
25 May 2022
The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022
Four high-quality US stocks to give shelter from the storm
Share tips

Four high-quality US stocks to give shelter from the storm

Professional investor Timothy Parton of the JPMorgan American Investment Trust picks four solid US stocks to buy now.
24 May 2022
Three undervalued mid-cap stocks with attractive prospects
Share tips

Three undervalued mid-cap stocks with attractive prospects

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing mid-cap stocks to buy now.
24 May 2022

Most Popular

The world’s hottest housing markets are faltering – is the UK next?
House prices

The world’s hottest housing markets are faltering – is the UK next?

As interest rates rise, house prices in the world’s most overpriced markets are starting to fall. The UK’s turn will come, says John Stepek. But will …
23 May 2022
The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022
Should you be worried about energy windfall tax proposals?
Energy

Should you be worried about energy windfall tax proposals?

Calls have been growing for a windfall tax on UK oil and gas producers. It's a popular idea, but is it a good one? And what does it mean for investors…
24 May 2022